Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Shire To Test Convenience Versus Familiarity In HAE With Approval Of Firazyr

Executive Summary

FDA’s Aug 25 approval of Shire PLC’s Firazyr (icatibant) for acute treatment of attacks of hereditary angioedema, with a label that allows patients to self-administer the drug, puts a convenience advantage up against a first-to-market advantage for the well-established C-1 esterase inhibitors.
Advertisement

Related Content

Phase II Success Positions Ra For Potential Blockbuster Opportunity In Myasthenia Gravis
The First Shall Be Fifth: Salix’s Recombinant C1 Esterase Inhibitor Enters Crowded HAE Market
Shire’s ViroPharma Purchase Aims To Build Rare Disease Giant
Ra Pharmaceuticals Inc.
Ra Pharma Aims For Oral Peptide Drugs Using Synthetic Amino Acids
FDA Relies On Experience To Judge Firazyr Self-Administration
Is Europe's HAE Market Big Enough To Sustain All The Competitors?

Topics

Advertisement
UsernamePublicRestriction

Register

PS053724

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel